

Initiatives to Improve Control, Resource Use, and Quality of Life Associated with Chemotherapy-Induced Nausea and Vomiting

Authors:	*Matti Aapro, ¹ *Rosanna Tarricone ^{2,3} 1. Cancer Centre, Clinique de Genolier, Genolier, Switzerland 2. Department of Social and Political Science, Bocconi University, Milan, Italy 3. Centre for Research on Health and Social Care Management (CERGAS), SDA Bocconi School of Management, Bocconi University, Milan, Italy *Correspondence to maapro@genolier.net or rosanna.tarricone@unibocconi.it
Disclosure:	Dr Aapro is, or has been, a consultant for Accord Pharmaceuticals, Amgen, BMS, Celgene, Clinigen Group, Eisai, Eli Lilly and company, Genomic Health (Exact Sciences), G1 Therapeutics, GlaxoSmithKline, Helsinn Healthcare SA, Hospira (Pfizer), Johnson & Johnson, Merck, Merck Serono (Merck KGaA), Mundipharma International Limited, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Tesaro (GSK), Teva Pharmaceutical, and Vifor Pharma; and has received honoraria for lectures at symposia from Accord Pharmaceuticals, Amgen, Bayer HealthCare Pharmaceuticals (Schering), Biocon, Boehringer Ingelheim, Cephalon, Chugai Pharmaceutical, Eisai, Dr. Reddy's Laboratories, Genomic Health (Exact Sciences), Glenmark Pharmaceuticals, GlaxoSmithKline, Helsinn Healthcare SA, Hospira (Pfizer), Ipsen, Janssen Biotech, Kyowa Kirin Group, Merck, Merck Serono (Merck KGaA), Mundipharma International Limited, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, Sanofi, Tesaro (GSK), Taiho Pharmaceutical, Teva Pharmaceutical, and Vifor Pharma. Prof Tarricone was a consultant for the European Commission and Zambon; and has received honoraria for presentations at congresses by Confindustria Dispositivi Medici, BARD Pharmaceuticals Ltd., Therakos® (Mallinckrodt Pharmaceuticals), Edwards Lifesciences, Stryker, Copma, Helsinn Healthcare SA, Medtronic, and Wellspect® HealthCare.
Acknowledgements:	Writing assistance was provided by Dr Julia Granerod, London, UK.
Support:	The publication of this article was supported by an educational grant from Helsinn Healthcare SA.
Received:	23.04.20
Accepted:	26.06.20
Keywords:	Adherence, antiemetics, cancer, chemotherapy-induced nausea and vomiting (CINV), guidelines.
Citation:	EMJ Oncol. 2020;8[Suppl 1]:2-13.

Abstract

Patients indicate that among the most feared side effects of cancer are chemotherapy-induced nausea and vomiting (CINV), with up to 80% of patients affected if appropriate prophylaxis is not administered. CINV affects patient quality of life, may interfere with chemotherapy compliance which can possibly influence cancer survival outcomes, and results in greater healthcare resource utilisation. An array of antiemetics that act on different receptors involved in CINV pathways are available, as are antiemetic guidelines from various international and national bodies (such as the American Society of Clinical Oncology [ASCO], Multinational Association for Supportive Care in Cancer [MASCC] and

European Society for Medical Oncology [ESMO], and National Comprehensive Cancer Network [NCCN]). Optimal management of CINV and other treatment-related side effects has been associated with improved quality of life, longer duration of anticancer treatments, and decreased utilisation of emergency care. Although progress has been made, there are still unmet needs, the greatest of which is the lack of complete nausea control.

INTRODUCTION

This review set out to identify the initiatives needed to achieve better cancer-induced nausea and vomiting (CINV) control worldwide. These include better adherence by healthcare professionals to evidence-based antiemetic guidelines and improved adherence by patients to antiemetic regimens. The use of netupitant with palonosetron (NEPA), a fixed combination therapy administered orally once per chemotherapy cycle, as well as mobile health (mHealth) apps may help with guideline adherence and patient compliance. Further developments will focus on the optimised use of new antiemetic compounds and alternative formulations to design simple and convenient regimens. In addition, as patient-specific risk factors are better defined, these can be incorporated into individualised regimens to obtain optimal antiemetic prophylaxis for that individual.

SEARCH STRATEGY

A literature search of PubMed was conducted in November 2019 without any date restrictions and using the following terms in various combinations: chemotherapy-induced nausea and vomiting, CINV, chemotherapy, nausea, vomiting, emesis, treatment, therapy, antiemetic, novel agent, NEPA, alternative treatment, alternative therapy/therapies, cost-effectiveness, economics, guideline, recommendation, control, developing country/countries, compliance, adherence, neurokinin 1 receptor antagonists (NK₁RA), olanzapine, 5-hydroxytryptamine-3 receptor antagonist (5-HT₃RA), dexamethasone, dopamine receptor antagonist, cannabinoids, ginger, mobile technology, and risk factor. Papers that related to the aim of the study and were written in English were included. The reference lists of acquired papers were also searched for further relevant articles.

NEED FOR IMPROVED CONTROL OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING

The global incidence of cancer is on the rise; 17 million new cases and 9.6 million deaths occurred worldwide in 2018 and it is estimated there will be 27.5 million new cases of cancer each year by 2040.¹ Patients with cancer experience many side effects while undergoing chemotherapy including alopecia, tiredness, and depression; however, the side effects most feared by patients are nausea and vomiting.^{2,3} Up to 80% of oncology patients may be affected by CINV if adequate prevention is not offered.⁴ CINV affects patient quality of life (QoL) including daily functioning, leisure activities, and the ability to eat and drink, and can result in complications including electrolyte imbalance, dehydration, and malnutrition.⁵ Importantly, CINV may also interfere with chemotherapy compliance or result in dose reduction and thus negatively influence cancer survival outcomes.^{6,7} In addition, emesis results in greater healthcare resource utilisation and higher cancer treatment costs as more inpatient, outpatient, and emergency department visits are required.⁸ Thus, CINV places a high burden on the individual, health services, and society.

Antiemetics are generally prescribed based on emetogenicity of the chemotherapy (high, moderate, low, or minimal) and type of CINV to be prevented. CINV can be acute or delayed, occurring 0–24 or 25–120 hours after chemotherapy, respectively. The incidence of delayed CINV varies depending on chemotherapy type, and it remains a challenge in terms of nausea control.⁹ CINV can also be anticipatory (a conditional response resulting from previous poor experience with chemotherapy), breakthrough (occurs despite the use of preventative drugs and may require rescue medication), and refractory (occurs after the unsuccessful use of antiemetics or

rescue medications in the previous treatment cycle). As the different types of CINV are controlled through different pathways and neurotransmitters, various approaches for prevention and treatment are required.¹⁰

Optimal management of CINV and other treatment-related side effects has been associated with improved QoL, longer duration of anticancer treatments, and decreased utilisation of emergency care.¹⁰ Although progress has been made in the management of CINV, there are still unmet needs, the greatest of which is the lack of complete nausea control.^{11,12} Multiple initiatives are needed to achieve better control of CINV (Figure 1) and thus reduce the burden on the individual and society. These initiatives are discussed in detail below.

AVAILABLE ANTIEMETICS

An array of antiemetics that act on different receptors involved in CINV pathways is available. The correct use of these antiemetics can prevent CINV in 70–80% of patients.¹³ Antiemetic guidelines are available from international bodies such as the American Society of Clinical Oncology (ASCO) and the Multinational Association of Supportive Care in Cancer (MASCC) and the European Society of Medical Oncology (ESMO), and national bodies such as the National Comprehensive Cancer Network (NCCN).^{14–17} An overview of recommended antiemetics by emetogenic risk of chemotherapy and CINV type is displayed in Table 1.^{14–17}

Neurokinin 1 Receptor Antagonists

The use of NK₁RA has advanced antiemetic therapy over the last 15 years following the initial approval of oral aprepitant in 2003.¹⁸ As a result, this class of drugs is currently included in recommended guidelines. Several other NK₁RA are now also available in many countries, including oral netupitant and intravenous (IV) fosnetupitant (available as fixed combinations with palonosetron), and oral rolapitant and IV fosaprepitant. The addition of a NK₁RA to an antiemetic regimen can significantly reduce episodes of vomiting and the need for additional medications.¹⁹ Numerous randomised controlled trials (RCT) have shown a significantly greater rate of complete response (i.e., no emesis and

no use of rescue medication) in patients on a three-drug regimen (i.e., NK₁RA, 5-HT₃RA, and dexamethasone) compared to those on a two-drug combination (i.e., 5-HT₃RA and dexamethasone) in both acute and delayed CINV.^{20–28} However, most of these studies showed no significant improvement in delayed nausea control. Similarly, a network meta-analysis of the comparative effectiveness of NK₁RA for highly emetogenic chemotherapy (HEC) concluded that NK₁RA-containing regimens are associated with higher complete response rates than regimens without NK₁RA.²⁹

The cost effectiveness of the addition of NK₁RA as antiemetics in patients with CINV has been demonstrated. A study from Hong Kong showed that the use of aprepitant compared to other drugs was associated with higher drug costs but a lower cost of emesis-related management. Thus, the aprepitant-containing regimen was deemed cost effective using the World Health Organization (WHO) cost-effectiveness threshold of three times gross domestic product per capita.³⁰ A Japanese cost-utility analysis reported that the addition of aprepitant, but not fosaprepitant, to the 5-HT₃RA and dexamethasone combination is cost effective.³¹ European studies have also demonstrated the cost effectiveness of aprepitant for CINV.^{32,33} A study that compared an aprepitant regimen (aprepitant, ondansetron, and dexamethasone) with a standard antiemetic regimen (ondansetron, dexamethasone, and metoclopramide) in patients with breast cancer in the UK reported that 78% of the cost of aprepitant was offset by reduced costs of healthcare resource utilisation. They reported an incremental cost-effectiveness ratio of £10,847/quality-adjusted life year with aprepitant compared to standard therapy; this is below the accepted UK threshold (£20,000–30,000/quality-adjusted life year) and suggests that aprepitant is cost effective for CINV prevention in UK patients with breast cancer.³² Similarly, a Belgian study confirmed that aprepitant-based CINV prevention was more effective and less costly than standard care.³³




Figure 1: Initiatives to achieve better control of chemotherapy-induced nausea and vomiting.

CINV: chemotherapy-induced nausea and vomiting.

Despite their efficacy and cost effectiveness, NK₁RA are underused in clinical practice. A retrospective study of administrative claims data from the USA showed almost universal use of dexamethasone and 5-HT₃RA; however, only 60% and 80% of patients received a NK₁RA in 2011 and 2016, respectively.¹⁸ Some institutions may limit the use of more expensive antiemetics by using a 5-HT₃RA and dexamethasone combination in the first cycle and only add in a NK₁RA if the patient experiences CINV.¹⁹ This practice is inconsistent with antiemetic guidelines for patients receiving HEC and for many receiving moderately emetogenic chemotherapy (MEC), and contradicts the fact that the first experience with chemotherapy is the most important in terms of CINV prevention. Patients who experience CINV during the first cycle are more likely to develop refractory or anticipatory CINV, whereas those whose CINV is controlled in the first cycle are more likely to do well in subsequent cycles.^{19,34} This highlights the importance of incorporating a NK₁RA into the antiemetic regimen as per the recommended guidelines.

Netupitant with Palonosetron

Netupitant is currently only available in combination with palonosetron (a 5-HT₃RA).¹⁸ NEPA represents the first antiemetic combination drug developed. Netupitant is a new, highly selective NK₁RA while palonosetron has unique pharmacological and clinical characteristics compared to older 5-HT₃RA as well as being more efficacious during the delayed CINV stage.³⁵ NEPA has been shown to be safe, well tolerated, and highly effective over multiple HEC or MEC cycles.³⁶ This antiemetic combination offers guideline-consistent prophylaxis by targeting two critical pathways associated with CINV in a single oral dose, administered only once per cycle.³⁷ Development of this antiemetic combination offers a solution to the inconsistencies evident in guideline-consistent care (i.e., an absence of a NK₁RA) for high-risk groups.³⁸ Economic constraints, as well as complexity and inconvenience of the oral aprepitant regimen (e.g., 3 days aprepitant plus 1-3 days 5-HT₃RA plus 1-4 days of dexamethasone), may also have played a role in the underutilisation of NK₁RA.^{37,38}

Table 1: Overview of recommended antiemetics by emetogenic risk of chemotherapy.¹⁴⁻¹⁷

Guideline	ASCO ¹⁴ (2017)		MASCC and ESMO ^{15,16} (2016)		NCCN ¹⁷ (2018)	
	Acute	Delayed	Acute	Delayed	Acute	Delayed
High (>90% frequency of emesis)	For AC, cisplatin, others, non-AC: DEX + 5-HT ₃ RA + NK ₁ RA + olanzapine For carboplatin AUC ≥4: DEX + 5-HT ₃ RA + NK ₁ RA	For non-AC, cisplatin, others: DEX + olanzapine For AC: olanzapine For carboplatin AUC ≥4: none	For AC, cisplatin, others, non-AC: DEX + 5-HT ₃ RA + NK ₁ RA ± olanzapine	For non-AC, cisplatin, others: DEX OR (metoclopramide + DEX) or (aprepitant + DEX) if aprepitant used in acute ± olanzapine For AC: none OR DEX or aprepitant (if aprepitant used in acute) ± olanzapine	For AC, carboplatin AUC ≥4, cisplatin, HEC single agents: DEX + 5-HT ₃ RA + NK ₁ RA OR olanzapine + palonosetron (5-HT ₃ RA) + DEX OR olanzapine + NK ₁ RA + 5-HT ₃ RA + DEX	For AC, carboplatin AUC ≥4, cisplatin, HEC single agents: DEX + aprepitant (NK ₁ RA, if used on Day 1) OR olanzapine OR olanzapine + aprepitant (NK ₁ RA, if used on Day 1) + DEX
Moderate (>30-90% frequency of emesis)	For carboplatin AUC <4, non-carboplatin: DEX + 5-HT ₃ RA	For non-carboplatin, carboplatin AUC <4: none OR DEX (for agents known to cause delayed CINV)	For carboplatin: DEX + 5-HT ₃ RA + NK ₁ RA For non-carboplatin: DEX + 5-HT ₃ RA	For carboplatin: none OR aprepitant (if aprepitant used in acute) For oxaliplatin, anthracycline, cyclophosphamide: DEX can be considered For others:none	For carboplatin AUC <4 and all other MEC agents: DEX + 5-HT ₃ RA OR olanzapine + palonosetron (5-HT ₃ RA) + DEX OR NK ₁ RA + 5-HT ₃ RA + DEX	For carboplatin AUC <4 and all other MEC agents: DEX OR 5-HT ₃ RA monotherapy OR olanzapine OR aprepitant (NK ₁ RA, if used on Day 1) ± DEX
Low (10-30% frequency of emesis)	DEX OR 5-HT ₃ RA	None recommended	DEX OR 5-HT ₃ RA OR dopamine receptor antagonists	None recommended	DEX OR dopamine receptor antagonists (prochlorperazine, metoclopramide) OR 5-HT ₃ RA	None recommended
Minimal (<10% frequency of emesis)	None recommended	None recommended	None recommended	None recommended	None recommended	None recommended

Acute refers to 0-24 hours after chemotherapy, delayed refers to 25-120 hours after chemotherapy.

5-HT₃RA: 5-HT₃ receptor antagonist; AC: anthracycline and cyclophosphamide combination; ASCO: American Society of Clinical Oncology; AUC: area under the curve; CINV: chemotherapy-induced nausea and vomiting; DEX: dexamethasone; ESMO: European Society of Medical Oncology; HEC: highly emetogenic chemotherapy; MASCC: Multinational Association of Supportive Care in Cancer; MEC: moderately emetogenic chemotherapy; NCCN: National Comprehensive Cancer Network; NK₁RA: neurokinin 1 receptor antagonist.

Cost-effectiveness analyses have shown benefit of NEPA over other drug combinations.^{39,40} Botteman et al.,⁴¹ who conducted the first economic analysis comparing NK₁RA regimens, reported that NEPA was more cost effective than an aprepitant-based regimen in patients undergoing HEC. In addition, NEPA with dexamethasone is not only superior to palonosetron with dexamethasone in preventing acute and delayed CINV following MEC and HEC, but it is also more cost effective.^{42,43} A real-life study has confirmed the benefit of NEPA seen in clinical trials; 630 patients were enrolled in a prospective, multicentre, noninterventional study where NEPA was effective in the prevention of CINV in patients who received carboplatin- and oxaliplatin-based MEC and QoL, and they remained stable during the course of chemotherapy.⁴⁴ Advantages and disadvantages of all antiemetics available for CINV are displayed in [Table 2](#).

CLINICIAN ADHERENCE TO RECOMMENDED GUIDELINES

Guidelines recommended by ASCO, MASCC and ESMO, and NCCN are based on the consensus opinions of international experts and most recent clinical trial data, and are regularly updated when new data become available. Despite being available and accessible, in many instances these guidelines are not followed. Very low adherence to antiemetic guidelines has been reported in clinical practice in the European Union (EU); only 16% of all patients on HEC or carboplatin-based regimens received the recommended combination of a NK₁RA, 5-HT₃RA, and dexamethasone.⁴⁵ In addition, 17% of patients on HEC or MEC received no antiemetics at all.⁴⁵ A further European study of >200 oncology nurses revealed that guideline awareness was generally low; less than one-half of nurses surveyed were familiar with the ASCO (46%) and MASCC and ESMO (40%) guidelines.⁴⁶ Key discrepancies between guideline recommendations and clinical use included underutilisation of the recommended NK₁RA plus 5-HT₃RA plus steroid combination on Day 1 (55%), and high use of 5-HT₃RA (50%) on Days 2-5 when a steroid (63% use) is recommended for patients on

HEC. Use of metoclopramide was also high in patients on both HEC and MEC, with approximately 30% and approximately 50% reporting use on Day 1 and Days 2-5, respectively.⁴⁶ Reasons for poor guideline adherence may have included the complexity of prophylactic treatment for HEC, mucositis, and depression in patients with cancer that may have affected compliance, concurrent use of multiple medications, physician workload, and suboptimal communication between provider and patient.¹⁸ Oncologists reported usage of weaker antiemetic regimens than necessary, underestimation of chemotherapy emetogenicity, and patient nonadherence because of administration errors or missed/delayed doses to be the main reasons for antiemetic treatment failure.⁴⁷

Following the recommended guidelines for CINV has been shown to improve patient outcome and reduce associated costs. A prospective, observational, multicentre study that enrolled chemotherapy-naïve adults initiating HEC or MEC for cancer showed that the guideline-consistent CINV prophylaxis cohort was 43% more likely than the guideline-inconsistent prophylaxis cohort to achieve a complete response (i.e., no emesis and no use of rescue medication) during the 120 hours after the first chemotherapy cycle.³⁸ Similarly, a Turkish study of 100 chemotherapy-naïve patients showed significant differences in complete control (i.e., no emetic episodes, rescue therapy, or nausea) and Functional Living Index Emesis (FLIE) score between the guideline (i.e., MASCC and ESMO 2014)-adherent and guideline-nonadherent groups.⁴⁸ The latter had a higher incidence of diarrhoea, headache, swallowing difficulties, and dark-coloured stool. Thus, clinicians and healthcare professionals are strongly encouraged to adhere to recommended guidelines to improve CINV control.

Antiemetic guidelines are valid in countries where drugs are available and reimbursed; however, this is not the case in some parts of the world. Bevoor et al.⁴⁹ conducted a study to look at utilisation patterns of antiemetics to control CINV with respect to standard international recommendations in 316 patients treated for cancer in India.

Table 2: Advantages and disadvantages of antiemetics available for chemotherapy-induced nausea and vomiting.

Agent	Advantages	Disadvantages
NK ₁ RA • Aprepitant • Fosaprepitant • Rolapitant oral	<ul style="list-style-type: none"> • Highly effective in delayed phase 	<ul style="list-style-type: none"> • Less effective in delayed nausea control • Expensive but may be cost effective • Not widely available in low- and middle-income countries
5-HT ₃ RA • Palonosetron • Ondansetron • Granisetron • Dolasetron • Tropisetron • Ramosetron	<ul style="list-style-type: none"> • Effective, especially in acute phase • Reduces delayed emesis (palonosetron) • Well tolerated 	<ul style="list-style-type: none"> • Not widely available in low- and middle-income countries
NEPA: fixed combination NK ₁ RA and 5-HT ₃ RA	<ul style="list-style-type: none"> • Safe • Well tolerated • Highly effective in acute and delayed phase • Convenient (i.e., single oral dose administered once per cycle) • Long half-life 	<ul style="list-style-type: none"> • Expensive but may be cost effective
Dexamethasone	<ul style="list-style-type: none"> • Inexpensive • Benefit in delayed nausea 	<ul style="list-style-type: none"> • Wide variety of adverse effects, especially if used for more than 1 day
Olanzapine	<ul style="list-style-type: none"> • Relatively inexpensive • Widely available • Ability to target multiple receptors with a single oral medication • Indicated by many guidelines • Indicated by MASCC/ESMO guideline as an excellent choice for breakthrough CINV and nausea control 	<ul style="list-style-type: none"> • Adverse effects make outpatient use somewhat difficult
Dopamine receptor antagonists • Prochlorperazine • Domperidone • Metoclopramide	<ul style="list-style-type: none"> • Inexpensive • Benefit in delayed nausea (prochlorperazine) • Benefit in breakthrough emesis (metoclopramide) 	<ul style="list-style-type: none"> • Adverse effects including neurological effects
Cannabinoids	<ul style="list-style-type: none"> • Not only antiemetic but reported to enhance appetite • Inexpensive 	<ul style="list-style-type: none"> • Limited data for definite conclusions • Unpredictable gastrointestinal absorption, poor bioavailability, delayed onset of action, and CNS effects (THC-rich cannabinoids)
Ginger	<ul style="list-style-type: none"> • No significant adverse effects • Inexpensive • Reported benefit in acute nausea 	<ul style="list-style-type: none"> • Limited data for definite conclusions

5-HT₃RA: 5-HT₃ receptor antagonist; CINV: chemotherapy-induced nausea and vomiting; CNS: central nervous system; ESMO: European Society of Medical Oncology; MASCC: Multinational Association of Supportive Care in Cancer; NEPA: netupitant and palonosetron; NK₁RA: neurokinin 1 receptor antagonist; THC: tetrahydrocannabinol.

They found numerous discrepancies including the prescription of ondansetron 32 mg, despite this not being recommended in guidelines; palonosetron 0.25 mg given for 3

days continuously rather than only on the first day of chemotherapy; dexamethasone given at a dose of 20 mg in many patients rather than 8–12 mg; use of promethazine and wide use of

metoclopramide which is not recommended in guidelines; and limited use of NK₁RA because of patient affordability and unwillingness of government insurance to fund the drug. Similarly, most Thai patients with cancer receiving HEC do not have access to NK₁RA and palonosetron because Thailand is a limited-resource country, despite international guidelines recommending the use of NK₁RA, 5-HT₃RA, and corticosteroid for prevention of CINV after HEC.⁵⁰ The use of olanzapine, which is 70% less costly than aprepitant, instead of a NK₁RA in combination with a 5-HT₃RA and dexamethasone, has been considered as an alternative option.⁵¹ An RCT found olanzapine to be as effective as aprepitant, both in combination with IV palonosetron and dexamethasone in terms of complete response in patients receiving HEC.⁵² Furthermore, olanzapine has shown superior efficacy over both NK₁RA in nausea prevention and oral aprepitant in the delayed phase of CINV and in nausea control.^{53,54} Further guidance is needed for those who cannot afford the antiemetic regimens recommended in current guidelines.

PATIENT FACTORS

Patient factors, such as younger age, female sex, low alcohol intake, anxiety, and a history of motion sickness or nausea during pregnancy, may also increase risk of CINV.^{55,56} However, these factors have not yet been incorporated into formal risk assessment, and treatment choice/recommendations are still largely based on emetogenicity of the chemotherapeutic agent.¹⁹ An algorithm has recently been developed to identify patients at high risk of CINV before each chemotherapy cycle.⁵⁷ Clinical application of this tool would allow patient risk factors to influence the selection of optimal antiemetic prophylaxis for that individual. In addition, use of drugs like NEPA, which is administered in a single oral dose once per cycle, will help to improve patient compliance and thus achieve better CINV control.³⁷

Patient compliance can be further improved by novel innovations such as mHealth, which is the use of mobile devices for healthcare delivery. There has been a recent boom in mobile technologies for the self-management of chronic diseases.⁵⁸ mHealth has the potential

to improve patient management of symptoms and compliance, reducing subsequent hospital visits and burden of disease. Less decline in health-related QoL and better overall survival was evident in patients with cancer who self-reported symptoms via web-based Symptom Tracking and Reporting (STAR), compared to patients who discussed symptoms only during clinical encounters with their oncologist or via telephone in the case of concerning symptoms.⁵⁹ A further study demonstrated improved survival in patients with advanced-stage lung cancer who self-reported symptoms using a web-mediated follow-up algorithm compared to patients who underwent routine follow-up with CT scans every 3–6 months.⁶⁰ However, despite its potential, evidence on the actual use of mobile technologies in cancer care is not promising. A recent cross-sectional, web-based survey across the USA and five European countries reported a much lower proportion of patients with cancer (28.46%) using mHealth than clinicians (76.97%).⁶¹ Patient concerns regarding use of mHealth included a preference for traditional means of communication with their doctor, lack of knowledge regarding the potential of information technology, and doubt about the reliability and effectiveness of mHealth for medical purposes. For mHealth to be effective, clinician and patient usage rates need to converge. Ideally, cancer apps should be designed to strengthen the patient–physician relationship and to ease physicians’ workload, as well as being tested for validity and effectiveness and fit the criteria for reimbursement.⁶¹ Further studies are currently underway, including an RCT to evaluate a mobile supportive care app for patients with metastatic lung cancer.⁶²

NOVEL THERAPIES

Despite progress, a significant proportion of patients still experience nausea and vomiting while receiving optimal treatment. Novel therapies, especially for the control of nausea, are still needed, with the ultimate goal of complete CINV control. Barhemsys® (formerly ADP421), a selective dopamine antagonist, has completed Phase III clinical development for the prophylaxis and treatment of postoperative nausea and vomiting (PONV).⁶³ The U.S.

Food and Drug Administration (FDA) has given the following label: indicated in adults for 1) prevention of PONV, either alone or in combination with an antiemetic of a different class; and 2) treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis.⁶⁴ Its role in CINV has yet to be determined. Several organisations (ASCO, ESMO, NCCN, and the Institute for Clinical and Economic Review [ICER]) have developed frameworks to assess the value of new cancer drugs to help clinicians, patients, and payers make decisions about treatments.⁶⁵ These frameworks differ in methods and approaches; however, they all help to promote a wider culture of allocative efficiency and prioritisation.⁶⁶

ALTERNATIVE THERAPIES

Alternative therapies have been used and tested for the control of CINV, including marijuana leaf extract, ginger, acupuncture, Chinese herbal medicine, and music therapy.⁶⁷⁻⁶⁹ Most studies that assessed the use of smoked marijuana or synthetic oral tetrahydrocannabinol medicines (THC; dronabinol, nabilone) in CINV have shown limited efficacy, were not sufficiently powered, and used outdated control antiemetic arms.⁷⁰ A small, pilot, double-blind, randomised trial of 16 patients with CINV after MEC, despite prophylaxis with a guideline-consistent antiemetic regimen, showed nabiximols, a THC/cannabidiol cannabis extract derived from the *Cannabis sativa* plant containing THC and cannabidiol in defined and near-equal amounts, to have substantial efficacy, high acceptability by patients, and manageable side effects for the secondary prevention of CINV.⁷¹ Early, though small, trials have shown THC to also improve appetite in these patients, with positive implications for overall performance

status.⁶⁸ There is also some evidence to suggest ginger may help to prevent acute emesis. An RCT in which ginger was added to a 5-HT₃RA plus dexamethasone combination showed reduction in acute, but not delayed, emesis.⁷² While these alternative therapies have been reported to be of help, further research is needed as there are insufficient data to draw any definitive conclusion.

CONCLUSION

Multiple initiatives are needed to achieve better control of CINV to minimise the negative impact on patients with cancer, improve patient outcomes, and reduce costs. Improved adherence to international antiemetic guidelines by healthcare professionals and compliance to antiemetic regimens by patients are both critical. NEPA may contribute to this improvement, as it is a fixed combination administered orally only once per chemotherapy cycle, as may the use of mHealth. Further developments will focus on the optimised use of new antiemetic compounds and alternative formulations to design simple and convenient regimens that ensure guideline adherence and patient compliance. Given the scarcity of resources, treatments must be assessed holistically, including all costs and benefits that accrue to the patient, healthcare system, and caregivers. The key question for decision makers, including medical doctors, in times of limited resources has shifted from 'does it work?' to 'is it worth it?'. As patient-specific risk factors are becoming better defined, these can be incorporated into individualised regimens to obtain optimal antiemetic prophylaxis for that individual. Further research should also focus on using real-world data to confirm existing regimens or to develop alternative improved regimens for better CINV control.

References

1. Cancer Research UK. Worldwide cancer statistics. 2018. Available at: <https://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer#heading-Zero>. Last accessed: November 2019.
2. National Cancer Institute (NCI). Side effects of cancer treatment. Available at: <https://www.cancer.gov/about-cancer/treatment/side-effects>. Last accessed: November 2019.
3. Hesketh P, "Prevention and treatment of chemotherapy-induced nausea and vomiting in adults," Ted W. (eds), UpToDate (2020), Waltham: UpToDate. Available at: <https://www.uptodate.com/contents/prevention-and-treatment-of-chemotherapy-induced-nausea-and-vomiting-in->

- adults. Last accessed: 29 June 2020.
4. Sommariva S et al. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. *Crit Rev Oncol Hematol*. 2016;99:13-36.
 5. Boccia R. Chemotherapy-induced nausea and vomiting: identifying and addressing unmet needs. *J Clin Outcomes Manage*. 2013;20(8):377-84.
 6. Neymark N et al. Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials. *Support Care Cancer*. 2005;13(10):812-8.
 7. Viale PH et al. Efficacy and cost: avoiding undertreatment of chemotherapy-induced nausea and vomiting. *Clin J Oncol Nurs*. 2012;16(4):E133-41.
 8. Burke TA et al. Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. *Support Care Cancer*. 2011;19(1):131-40.
 9. Karthaus M et al. Neurokinin-1 receptor antagonists: review of their role for the prevention of chemotherapy induced nausea and vomiting in adults. *Expert Rev Clin Pharmacol*. 2019;12(7):661-80.
 10. Natale JJ. Overview of the prevention and management of CINV. *Am J Manag Care*. 2018;24(18):S391-7.
 11. Aapro M. CINV: still troubling patients after all these years. *Support Care Cancer*. 2018;26(Suppl 1):5-9.
 12. Aapro M et al. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective. *Future Oncol*. 2019;15(10):1067-84.
 13. Mellin C et al. Antiemetic guidelines: using education to improve adherence and reduce incidence of CINV in patients receiving highly emetogenic chemotherapy. *Clin J Oncol Nurs*. 2018;22(3):297-303.
 14. Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol*. 2017;35(28):3240-61.
 15. Roila F et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. *Ann Oncol*. 2016;27(Suppl 5):v119-33.
 16. Multinational Association of Supportive care in Cancer (MASCC). MASCC/ESMO antiemetic guideline 2016 V.1.4. 2019. Available at: <https://mascc.memberclicks.net/antiemetic-guidelines>. Last accessed: 29 June 2020.
 17. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Antiemesis: version 3. 2018. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx. Last accessed: 29 June 2020.
 18. O'Sullivan CC et al. Ten-year trends in antiemetic prescribing in patients receiving highly emetogenic chemotherapy. *J Natl Compr Canc Netw*. 2018;16(3):294-9.
 19. Navari RM et al. Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting. *Onco Targets Ther*. 2018;11:6459-78.
 20. Rapoport B et al. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). *Support Care Cancer*. 2015;23(11):3281-8.
 21. Rapoport BL et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, Phase 3 trials. *Lancet Oncol*. 2015;16(9):1079-89.
 22. Schwartzberg LS et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, Phase 3 trial. *Lancet Oncol*. 2015;16(9):1071-8.
 23. Hesketh PJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin – the Aprepitant Protocol 052 Study Group. *J Clin Oncol*. 2003;21(22): 4112-9.
 24. Hesketh PJ et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. *Ann Oncol*. 2014;25(7):1340-6.
 25. Hu Z et al. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. *Support Care Cancer*. 2014;22(4):979-87.
 26. Saito H et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled Phase 3 trial. *Ann Oncol*. 2013;24(4):1067-73.
 27. Schmoll HJ et al. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. *Ann Oncol*. 2006;17(6):1000-6.
 28. Takahashi T et al. Multicenter, Phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. *Cancer Sci*. 2010;101(11):2455-61.
 29. Abdel-Rahman O. Neurokinin-1 inhibitors in the prevention of nausea and vomiting from highly emetogenic chemotherapy: a network meta-analysis. *Ther Adv Med Oncol*. 2016;8(5):396-406.
 30. Chan SL et al. Economic analysis of aprepitant-containing regimen to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Hong Kong. *Asia Pac J Clin Oncol*. 2014;10(1):80-91.
 31. Kashiwa M et al. Comparative cost-utility analysis between aprepitant- and fosaprepitant-containing regimens to prevent chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan. *Clin Ther*. 2019;41(5):929-42.
 32. Humphreys S et al. Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK. *Cancer Manag Res*. 2013;5:215-24.
 33. Annemans L et al. Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. *Support Care Cancer*. 2008;16(8):905-15.
 34. Molassiotis A et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. *J Pain Symptom Manage*. 2014;47(5):839-48.
 35. Aapro M et al. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, Phase 3 trial versus oral palonosetron. *Support Care Cancer*. 2017;25(4):1127-35.

36. Gralla RJ et al. A Phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. *Ann Oncol*. 2014;25(7):1333-9.
37. Hesketh PJ et al. A review of NEPA, a novel fixed antiemetic combination with the potential for enhancing guideline adherence and improving control of chemotherapy-induced nausea and vomiting. *Biomed Res Int*. 2015;2015:651879.
38. Aapro M et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). *Ann Oncol*. 2012;23(8):1986-92.
39. Restelli U et al. Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. *BMJ Open*. 2017;7(7):e015645.
40. Cawston H et al. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. *Drugs Context*. 2017;6:212298.
41. Botteman M et al. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis. *Support Care Cancer*. 2020;28(2):85-66.
42. Aapro M et al. A randomized Phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. *Ann Oncol*. 2014;25(7):1328-33.
43. Giuliani J, Bonetti A. Netupitant plus palonosetron (NEPA) for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) in highly and moderately (AC-based chemotherapy) emetogenic cancer treatment: a cost-effective choice. *Expert Rev Pharmacoecon Outcomes Res*. 2019;19(5):505-8.
44. Karthaus M et al. Antiemetic prophylaxis with NEPA in patients with moderately emetogenic chemotherapy – quality of life and efficacy data from the interim analysis of a prospective non-interventional study. Abstract A16. AGSMO Annual Congress, 15-16 March, 2019.
45. Aapro MS et al. Evaluation of practice patterns for prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) and antiemetics guideline (GL) adherence based on real-world prescribing data. *Ann Oncol*. 2018;29(Suppl 8):viii603-40.
46. Dielenseger P et al. Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey. *Support Care Cancer*. 2019;27(11):4099-106.
47. Aapro M et al. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: a quantitative market research-based survey. *Cancer Reports*. 2018;1(4):e1127.
48. Abunahlah N et al. Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life. *Int J Clin Pharm*. 2016;38(6):1464-76.
49. Bevoor DB et al. Drug utilization evaluation of antiemetics in chemotherapy induced nausea and vomiting in oncology setting. *Acta Scientific Pharmaceutical Sciences* 2018;2(8):30-9.
50. Tienchaiananda P et al. A randomized, double-blind, placebo-controlled study evaluating the efficacy of combination olanzapine, ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving doxorubicin plus cyclophosphamide. *Ann Palliat Med*. 2019;8(4):372-80.
51. Yokoe T et al. Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. *Oncologist*. 2019;24(6):e347-57.
52. Navari RM et al. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized Phase III trial. *J Support Oncol*. 2011;9(5):188-95.
53. Bošnjak SM et al. Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK¹) receptor antagonists. *Support Care Cancer*. 2017;25(5):1661-71.
54. Zhang Z et al. Olanzapine-based triple regimens versus neurokinin-1 receptor antagonist-based triple regimens in preventing chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy: a network meta-analysis. *Oncologist*. 2018;23(5):603-16.
55. Sekine I et al. Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis. *Cancer Sci*. 2013;104(6):711-7.
56. Molassiotis A et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. *J Pain Symptom Manage*. 2014;47(5):839-48.
57. Dranitsaris G et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. *Ann Oncol*. 2017;28(6):1260-7.
58. World Health Organization (WHO). mHealth: new horizons for health through mobile technologies. 2011. Available at: https://www.who.int/goe/publications/goe_mhealth_web.pdf? Last accessed: 29 June 2020.
59. Basch E et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. *JAMA* 2017;318(2):197-8.
60. Denis F et al. Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. *J Natl Cancer Inst*. 2017;109(9):dix029.
61. Tarricone R et al. The mHealth divide between clinicians and patients in cancer care: results from a cross-sectional international survey. *JMIR Mhealth Uhealth* 2019;7(9):e13584.
62. Ciani O et al. Lung cancer app (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer. *BMJ Open*. 2019;9(2):e025483.
63. Acacia Pharma. BARHEMSYS® – postoperative nausea & vomiting (PONV). Available at: <http://acaciapharma.com/pipeline/barhemsys-apd421>. Last accessed: February 2020.
64. U.S. Food and Drug Administration (FDA). BARHEMSYS® (amisulpride). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209510s000lbl.pdf. Last accessed: March 2020.
65. Bentley TG et al. Validity and reliability of value assessment frameworks for new cancer drugs. *Value in Health*. 2017;20(2):200-5.
66. Boscolo PR et al. Measuring value in healthcare: a comparative analysis of value-based frameworks. *Clin Ther*. 2020;42(1):34-43.
67. Davis MP. New therapies for antiemetic prophylaxis for chemotherapy. *J Community Support Oncol*. 2016;14(1):11-20.
68. Davis MP. Cannabinoids for symptom management and cancer therapy: the evidence. *J Natl Compr Canc Netw*. 2016;14(7):915-22.
69. Ma TT et al. Prevention of chemotherapy-induced nausea and vomiting with acupuncture: a protocol for systematic review and meta-analysis. *Medicine (Baltimore)*. 2020;99(3):e18828.

70. Duran M et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. *Br J Clin Pharmacol*. 2010;70(5):656-63.
71. Mersiades AJ et al. Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). *BMJ Open*. 2018;8(9):e020745.
72. Ryan JL et al. Ginger (*Zingiber officinale*) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. *Supp Care Cancer*. 2012;20(7):1479-89